Free Trial
→ Here’s Why Trump Won’t End The Iran War (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:TECX

Tectonic Therapeutic Q3 2026 Earnings Date & Estimates

Tectonic Therapeutic logo
$23.33 +0.58 (+2.55%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$23.31 -0.02 (-0.09%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tectonic Therapeutic is expected to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for November 6, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Tectonic Therapeutic in Q3 2026

Tectonic Therapeutic is expected to post earnings of -$1.38 per share. In the same quarter a year earlier Tectonic Therapeutic reported -$1.02 per share. Tectonic Therapeutic last reported on August 6, 2026, posting -$1.18 per share and beating the -$1.35 consensus estimate. Tectonic Therapeutic has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$1.38
Prior-Year EPS
-$1.02

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$1.18 (Beat by +$0.17)
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Tectonic Therapeutic Q3 2026 Earnings FAQ

Tectonic Therapeutic (NASDAQ:TECX) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Tectonic Therapeutic's Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Tectonic Therapeutic to post earnings of -$1.38 per share for Q3 2026.

Tectonic Therapeutic Earnings Headlines

Tectonic Therapeutic (NASDAQ:TECX) Stock Rating Raised to Sell at Wall Street Zen
October 10 at 1:06 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31104173
Tectonic Therapeutic (NASDAQ:TECX) Insider Peter Mcnamara Sells 536 Shares of Stock
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31083238
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end.tc pixel
October 10 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Analysts Offer Insights on Healthcare Companies: Tectonic Therapeutic (TECX) and Solid Biosciences (SLDB)
October 1, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SLDB-Q/pressreleases/4903204/analysts-offer-insights-on-healthcare-companies-tectonic-therapeutic-tecx-and-solid-biosciences-sldb/
Tectonic Therapeutic Says TX2100 Phase 1a Trial Met Primary Objectives
September 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/tectonic-therapeutic-says-tx2100-phase-142937693.html
Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
September 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/29/3370759/0/en/tectonic-therapeutic-announces-favorable-phase-1-safety-tolerability-and-pk-results-for-tx2100-a-novel-approach-for-the-treatment-of-hereditary-hemorrhagic-telangiectasia-hht.html
See More Tectonic Therapeutic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tectonic Therapeutic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tectonic Therapeutic and other key companies, straight to your email.

About Tectonic Therapeutic

Tectonic Therapeutic (NASDAQ:TECX) (NASDAQ: TECX) is a clinical-stage biotechnology company developing biologic medicines that target G protein-coupled receptors (GPCRs). These receptors play important roles in numerous biological processes and are established targets for a range of therapeutic treatments, but many remain difficult to address with conventional drug-discovery approaches.

The company uses its proprietary GEODe platform to identify and develop antibodies and other biologic molecules designed to modulate GPCR activity. Its research and development efforts are focused on creating therapies for serious diseases in areas where current treatment options may be limited.

Tectonic’s lead program, TX45, is an engineered relaxin-based therapeutic intended to activate the RXFP1 receptor. The program has been investigated for potential treatment of pulmonary arterial hypertension and other cardiovascular conditions. Tectonic Therapeutic is based in the United States and focuses primarily on advancing its internal discovery and clinical development pipeline.

View Tectonic Therapeutic Profile
Earnings Tools